Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of CER-001 in familial primary hypoalphalipoproteinemia
2015-003713-23Phase 3Terminated
- Sponsor
- ABIONYX Pharma
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in familial hypoalphalipoproteinaemia (FHA) comparing CER-001 with Placebo (2 arms). Primary endpoint: Primary efficacy parameter. Started Sep 2015; status: terminated.
02
Drugs
CER-001
03
Conditions
familial hypoalphalipoproteinaemia (FHA)
Beyond the preview
Go deeper on 2015-003713-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003713-23.